Clinical trialNCT06500273RecruitingPhase 2Interventional

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

SponsorAllogene TherapeuticsEnrollment250Large B-cell Lymphoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. In this study, participants with MRD are randomized 1:1 to treatment with cema-cel or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide. Prior to August 2025, participants may also have received an anti-CD52 monoclonal antibody, ALLO-647, as part of their lymphodepletion regimen.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Allogene Study Director
Allogene Therapeutics, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

82 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Icon Cancer Centre Wesley
Auchenflower, Queensland, Australia
Karthik Nath, MD
Recruiting
Royal Hobart Hospital
Hobart, Tasmania, Australia
Anna Johnston, MD
Recruiting
Monash Health
Clayton, Victoria, Australia
Danielle Oh, MD
Recruiting
St. Vincent'S Hospital Melbourne
Fitzroy, Victoria, Australia
Matthew Ku, MD
Recruiting
Austin Health
Heidelberg, Victoria, Australia
Denise Lee, MD
Recruiting
Hollywood Private Hospital
Nedlands, Western Australia, Australia
Chan Cheah, MD
Recruiting

Canada

Arthur Je Child Comprehensive Cancer Centre
Calgary, Alberta, Canada
Mona Shafey, MD
Recruiting
Queen Elizabeth Ii Health Sciences Centre
Halifax, Nova Scotia, Canada
Mahmoud Elsawy, MD
Recruiting
Princess Margaret Cancer Centre - University Health Network
Toronto, Ontario, Canada
John Kuruvilla, MD
Recruiting
Chum - University of Montreal Hospital Centre
Montreal, Quebec, Canada
Xavier Deschenes-Simard, MD
Recruiting
Centre Integre Universitaire de Sante Et Services Sociaux de L'Est de I'Lle de Montreal / Installation Hopital Maisonneuve-Rosemont
Montreal, Quebec, Canada
Sandra Cohen, MD
Recruiting
Hopital de'L'Enfant-Jesus
Québec, Quebec, Canada
Christopher Lemieux, MD
Recruiting

South Korea

Pusan National University Hospital
Seogu, Busan, South Korea
Shin Ho-jin, MD
Recruiting
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea
Hyeon-Seok Eom, MD
Recruiting
Chonnam National University, Hwasun Hospital
Hwasun, Jeollanam-do, South Korea
Deok-Hwan Yang, MD
Recruiting
Asan Medical Center
Seoul, Seoul, South Korea
Dok Yoon, MD
Recruiting
Samsung Medical Center
Seoul, Seoul, South Korea
Seok Kim, MD
Recruiting
Seoul National University
Seoul, Seoul, South Korea
Youngil Koh, MD
Recruiting
Severance Hospital, Yonsei University Health System
Seoul, Seoul, South Korea
Jin Seok Kim, MD
Recruiting
the Catholic University of Korea, Yeouido St. Mary'S Hospital
Seoul, Seoul, South Korea
Youngwoo Jeon, MD
Recruiting

United States

Banner Md Anderson Cancer Center
Gilbert, Arizona, United States
Matthew Ulrickson, MD
Recruiting
Genesis Cancer and Blood Institute
Hot Springs, Arkansas, United States
Stephen Divers, MD
Recruiting
Alta Bates Summit Medical Center
Berkeley, California, United States
Oleg Krijanovski, MD
Recruiting
City of Hope
Duarte, California, United States
Geoffrey Shouse, MD
Recruiting
Cedars-Sinai Medical Center
Los Angeles, California, United States
Akil Merchant, MD
Recruiting
University of California, Los Angeles
Los Angeles, California, United States
Sven DeVos, MD
Recruiting
University of California, Davis Comprehensive Cancer Center
Sacramento, California, United States
Naseem Esteghamat, MD
Recruiting
University of California, San Diego
San Diego, California, United States
Ayad Hamdan, MD
Recruiting
University of California, San Francisco
San Francisco, California, United States
Michael Spinner, MD
Recruiting
Rocky Mountain Cancer Centers
Denver, Colorado, United States
John Burke, MD
Recruiting
Medical Oncology Hematology Consultants
Newark, Delaware, United States
Jamal Misleh, MD
Recruiting
Medstar Georgetown University Hospital
Washington D.C., District of Columbia, United States
Kieron Dunleavy, MD
Recruiting
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida, United States
Yuliya Linhares, MD
Recruiting
Advent Health Cancer Institute
Orlando, Florida, United States
Rushang Patel, MD
Recruiting
Orlando Health Cancer Institute
Orlando, Florida, United States
Abhishek Chilkulwar, MD
Recruiting
Moffitt Cancer Center
Tampa, Florida, United States
Frederick Locke, MD
Recruiting
Augusta University Georgia Cancer Center
Augusta, Georgia, United States
Locke Bryan, MD
Recruiting
Northwestern University - Feinberg School of Medicine
Chicago, Illinois, United States
Reem Karmali, MD
Recruiting
Rush University Medical Center
Chicago, Illinois, United States
Sunita Nathan, MD
Recruiting
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana, United States
Sunil Babu, MD
Recruiting

42 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cyclophosphamide →Fludarabine →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 18 Jun 2024
Primary completion: 31 Dec 2027
Completion: 31 Dec 2032
Last update posted: 30 Jul 2026
Registered enrollment: 250
Registry id: NCT06500273

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.